What Should I do About a Tramadol Overdose?

Tramadol hydrochloride sustained-release tablets are indicated for moderate to severe pain.

Tramadol hydrochloride sustained-release tablets are indicated for moderate to severe pain.

Drug Name

Tramadol hydrochloride sustained-release tablets

Drug type

Prescription drugs, medicines for medical workers' injuries

Special medicine

Psychotropic drugs

Use classification

Analgesics

Tramadol hydrochloride sustained-release tablets ingredients

The active ingredient of this product is tramadol hydrochloride.
Chemical name: (±) -E-2-[(dimethylamino) methyl] -1- (3-methoxyphenyl) cyclohexanol hydrochloride.
Chemical Structure:

Molecular formula: C ₁₆ H ₂₅ NO ₂ · HCl
Molecular weight: 299.84

Tramadol hydrochloride sustained-release tablets

This product is a white or off-white shaped film-coated tablet with dividing lines on one side.

Tramadol hydrochloride sustained-release tablets indications

For moderate to severe pain.

Tramadol hydrochloride sustained-release tablets specifications

100mg

Tramadol hydrochloride sustained release tablets

Swallow and do not chew.
The dosage of this product depends on the degree of pain. Generally, it is started from 50mg (half tablet) each time and taken once every 12 hours. The dosage can be adjusted according to the pain of the patient. For adults and patients with moderate pain over 14 years of age, the single dose is 50 ~ 100mg (half tablet-1 tablet). Children over 1 year old with a weight of not less than 25 kg take a dose of 1 to 2 mg per kg of body weight. The minimum dose of this product is 50 mg (half tablet). The maximum daily dose usually does not exceed 400 mg (4 tablets). Larger doses can also be considered when treating cancerous pain. Hepatic and renal insufficiency should be used as appropriate. The dosage of elderly patients should be reduced. The interval between two doses should not be less than 8 hours.
The above recommended doses are for reference only. In principle, the lowest analgesic dose should be selected. Take as directed.

Adverse reactions of tramadol hydrochloride sustained-release tablets

The adverse reactions of this product are:
1. Systemic: allergic reactions, allergic reactions;
2. Cardiovascular system: hypotension, tachycardia, extremely rare hypertension and bradycardia;
3. Digestive system: nausea *, vomiting *, constipation *, gastrointestinal disorders, dry mouth * ;
4. Central nervous system: dizziness *, drowsiness *, headache, visual abnormality, emotional instability, euphoria, hypoactivity, hyperfunction, cognitive and sensory disorders, convulsions, mental disorders, drug dependence, hallucinations, withdrawal synthesis Signs include: excitement, anxiety, nervousness, insomnia, hyperkinesis, tremor, gastrointestinal symptoms;
5. Skin: sweating *, pruritus, rash, urticaria, angioedema;
6. Urogenital system: dysuria, urinary retention;
7. Respiratory system: dyspnea, bronchospasm, respiratory depression. (Note: * is a common adverse reaction, the incidence is 1%)

Tramadol hydrochloride sustained-release tablets contraindications

Those who are highly sensitive to this product and those who are acutely poisoned by alcohol, sleeping pills, analgesics or other psychotropic substances.

Precautions for tramadol hydrochloride sustained-release tablets

1. This product is used cautiously for those who are opioid dependent or have a tendency to abuse drugs and dependence; acute alcoholism and use of sleeping pills, central analgesics (including opioids and psychotropic drugs); combined with central nervous system sedative drugs When shock occurs; monoamine oxidase inhibitors are being received or used within the past 14 days; severe liver or kidney damage; head injury, increased intracranial pressure, unexplained disturbances of consciousness, respiratory central and respiratory dysfunction, respiratory depression.
Seizures have been reported at therapeutic doses, and the risk of seizures may increase when the dosage exceeds the upper limit of conventional daily doses. For patients with a history of epilepsy or prone to seizures, use it only as a last resort. Patients taking tramadol and medications that lower the seizure threshold increased the risk of seizures.
Use this product with caution in infants under 1 year old.
2. Long-term use of this product should pay attention to the formation of drug resistance or drug dependence, and the course of treatment should not exceed the need for treatment. And this product is not suitable for alternative therapeutic drugs.
Although it is an opioid agonist, it does not inhibit the withdrawal symptoms of morphine.
3. In the case of commonly used amount, this product may also affect the patient's ability to drive or respond to mechanical operations.
4. If the dosage exceeds the prescribed dose or combined with the central nervous system sedative, respiratory depression may occur.
5. In patients with impaired liver and kidney function, due to their prolonged half-life, the interval between medications should be appropriately extended.
6. Heart disease should be used with caution.
7. According to the relevant regulations of the national pharmaceutical administration, this product is strictly forbidden to be used in food, feed processing and breeding.

Tramadol hydrochloride sustained-release tablets for pregnant and lactating women

This product should not be used by pregnant or lactating women.

Tramadol hydrochloride sustained-release tablets for children

Children over 1 year of age who weigh at least 25 kg take 1 to 2 mg per kg of body weight. The minimum dose of this product is 50 mg (half tablet), so this product is not recommended for patients under 14 years old.

Tramadol hydrochloride sustained-release tablets for elderly

Use with caution or reduce as appropriate.

Tramadol hydrochloride sustained-release tablets drug interactions

1. When combined with CNS drugs or alcohol, it can enhance the sedative effect of this product, especially the respiratory depression effect. In combination with nerve blockers, convulsions have been reported in individual cases.
2. Patients receiving monoamine oxidase (MAO) inhibitors, and then taking this product may have serious effects on the central nervous system, circulation, and respiratory system.
3. The effect of cimetidine on this product is very small.
4. Carbamazepine-containing drugs: can reduce the analgesic effect of this product.
5. Combination with selective serotonin reuptake inhibitors (SSRIs), tricyclic anti-sedatives (TCAs), antipsychotics and other drugs that lower the threshold of seizures: extremely rare seizures.
6. Co-administration with selective serotonin reuptake inhibitors (SSRIs) can lead to increased serotonin activation (serotonin syndrome).
7. There have been individual reports of interactions with coumarin anticoagulants leading to an increase in the International Normalized Ratio (INR). So when patients start taking tramadol, anticoagulants should be used with caution.

Tramadol hydrochloride sustained-release tablets overdose

Typical symptoms of overdose of this product:
Vomiting, disturbance of consciousness, coma, generalized seizures, hypotension, tachycardia, cardiovascular failure, dilation or dilation of the pupils, sedation and coma, seizures and respiratory depression, and even respiratory arrest may occur. Serious cases can be fatal.
The above symptoms can be counteracted by the use of opioid receptor antagonists (such as naloxone). Because its action time is shorter than that of tramadol hydrochloride, attention should be paid to small doses. In addition, tracheal intubation, artificial respiration, etc. can be used as appropriate. When convulsions occur, benzodiazepines can be considered.
Hemodialysis or filtration can remove a very small amount of tramadol from the serum. Therefore, hemodialysis or filtration alone is not suitable for the detoxification of tramadol acute poisoning.
Emptying the stomach contents is beneficial for removing any unabsorbed drug, especially when a slow release formulation is taken.

Tramadol hydrochloride sustained-release tablets pharmacology and toxicology

Tramadol hydrochloride mainly acts on pain-specific receptors in the central nervous system. No smooth muscle spasm effect. At the recommended dose, the unusual respiratory depression listed under Adverse Reactions does not occur, and it has no significant effect on hemodynamics. Resistance and dependence are low. Teratogenicity of tramadol was not found in animal tests.

Pharmacokinetics of tramadol hydrochloride sustained-release tablets

After oral administration, this product is quickly and completely absorbed through the gastrointestinal tract, and is distributed in tissues and organs with abundant blood flow. The sustained-release preparation can prolong the maintenance time of the therapeutic concentration of tramadol hydrochloride in the body and reduce the fluctuation of blood drug concentration. This product is metabolized in the liver. Prototype drugs and metabolites are almost completely excreted from the kidneys.

Tramadol hydrochloride sustained-release tablets

Shaded and sealed.

Tramadol hydrochloride sustained-release tablets packaging

Aluminum-plastic packaging.
(1) 1 plate per box, 10 pieces per plate;
(2) 1 plate per box, 6 pieces per plate.

Tramadol hydrochloride sustained-release tablets

36 months

Tramadol hydrochloride sustained-release tablets

WS1- (X-387) -2004Z ^[1]